A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the B...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Robinson, Hannah R., Qi, Junpeng, Cook, Erika M., Nichols, Cydney, Dadashian, Eman L., Underbayev, Chingiz, Herman, Sarah E. M., Saba, Nakhle S., Keyvanfar, Keyvan, Sun, Clare, Ahn, Inhye E., Baskar, Sivasubramanian, Rader, Christoph, Wiestner, Adrian
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073325/
https://ncbi.nlm.nih.gov/pubmed/29743179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-830992
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky